ClinicalTrials.gg
CompletedNCT06774313Updated May 6, 2026

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

A Phase 1 interventional study of ABBV-142 and ABBV-142 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-142
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Parts:

  • Volunteers in general good health.

Part 3, ONLY:

HAN CHINESE Participants:

  • Participant must be first- or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health.
  • First-generation participants will have been born in China to two parents and four grandparents, who were also born in China, and are of full Chinese descent.
  • Second-generation participants born outside of China must have two parents and four grandparents born in China and are of full Chinese descent.

OR

JAPANESE Participants:

  • Participant must be first- or second-generation Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health.
  • First-generation participants will have been born in Japan to two parents and four grandparents born in Japan and are of full Japanese descent.
  • Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan and are of full Japanese descent.

Exclusion criteria

Exclusion Criteria:

  • History of any illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
  • Use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.
  • History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Part 1: Group 1

    Participants will receive ABBV-142 Dose A or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 1: Group 2

    Participants will receive ABBV-142 Dose B or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 1: Group 3

    Participants will receive ABBV-142 Dose C or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 1: Group 4

    Participants will receive ABBV-142 Dose D or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 1: Group 5 (Optional)

    Participants will receive ABBV-142 Dose TBD or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 2: Group 6

    Participants will receive ABBV-142 Dose B or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 2: Group 7

    Participants will receive ABBV-142 Dose C or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 3: Group 8

    Han Chinese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

  • Experimental
    Part 3: Group 9

    Japanese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.

    Drug: ABBV-142 · Drug: Placebo

Interventions

  • DrugABBV-142

    Intravenous (IV) Infusion

  • DrugABBV-142

    Subcutaneous (SC) Injection

  • DrugPlacebo

    IV Infusion

  • DrugPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Day 120

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-142

    Cmax of ABBV-142 will be assessed.

    Time frame: Up to Day 120

  3. Time to Cmax (Tmax) of ABBV-142

    Tmax of ABBV-142 will be assessed.

    Time frame: Up to Day 120

  4. Area Under the Serum Concentration-time Curve (AUC) of ABBV-142 from Time 0 to the Time of Last Measurable Concentration (AUCt)

    AUCt of ABBV-142 will be determined.

    Time frame: Up to Day 120

  5. AUC of ABBV-142 from Time 0 to Infinity (AUCinf)

    AUCinf of ABBV-142 will be assessed.

    Time frame: Up to Day 120

  6. Terminal Phase Elimination Rate Constant (β) of ABBV-142

    Terminal phase elimination rate constant (β) of ABBV-142 will be assessed.

    Time frame: Up to Day 120

  7. Terminal Phase Elimination Half-life (t1/2) of ABBV-142

    Terminal phase elimination half-life (t1/2) of ABBV-142 will be assessed.

    Time frame: Up to Day 120

  8. Dose Normalized Cmax of ABBV-142

    Dose normalized Cmax of ABBV-142 will be assessed.

    Time frame: Up to Day 120

  9. Dose Normalized AUC of ABBV-142

    Dose normalized AUC of ABBV-142 will be assessed.

    Time frame: Up to Day 120

07

Study locations

1 site
  • Acpru /Id# 271899
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Apr 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 14, 2025
StartActual
Jan 22, 2025
Primary completionActual
Apr 8, 2026
CompletionActual
Apr 8, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06774313
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Jan 22, 2025
Primary completion
Apr 8, 2026
Completion
Apr 8, 2026
Last update
May 6, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion